Do New Protease Inhibitors Offer Improved Management Options? Issues of PI Tolerability and Safety

Journal of Acquired Immune Deficiency Syndromes

Volumn 35, Issue SUPPL. 1, 2004, Pages

  Sax, Paul E ^a  

^a BRIGHAM AND WOMEN S HOSPITAL   (United States)

Author keywords

AIDS; Antiretroviral therapy tolerability; HIV drug safety; HIV infection; Protease inhibitor therapy

Indexed keywords

ABACAVIR PLUS LAMIVUDINE PLUS ZIDOVUDINE; AMPRENAVIR PHOSPHATE; ANTACID AGENT; ATAZANAVIR; ATENOLOL; DARUNAVIR; DILTIAZEM; EFAVIRENZ; FIBRIC ACID DERIVATIVE; HISTAMINE H2 RECEPTOR ANTAGONIST; INDINAVIR; LAMIVUDINE; LAMIVUDINE PLUS ZIDOVUDINE; LOPINAVIR; NELFINAVIR; PROTEINASE INHIBITOR; PROTON PUMP INHIBITOR; RITONAVIR; RNA DIRECTED DNA POLYMERASE INHIBITOR; SAQUINAVIR; STATIN; STAVUDINE; TIPRANAVIR; UNCLASSIFIED DRUG; ZIDOVUDINE;

BONE METABOLISM; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CEREBROVASCULAR ACCIDENT; CEREBROVASCULAR DISEASE; CLINICAL TRIAL; CONFERENCE PAPER; CONTROLLED CLINICAL TRIAL; DIABETES MELLITUS; DIARRHEA; DOSE RESPONSE; DRUG CHOICE; DRUG DOSE REGIMEN; DRUG SAFETY; DRUG TOLERABILITY; GASTROINTESTINAL SYMPTOM; GLUCOSE INTOLERANCE; GLUCOSE METABOLISM; HEART INFARCTION; HEPATITIS; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; HYPERBILIRUBINEMIA; HYPERCHOLESTEROLEMIA; HYPERLIPIDEMIA; HYPERLIPOPROTEINEMIA; HYPERTRIGLYCERIDEMIA; INSULIN RESISTANCE; ISCHEMIC HEART DISEASE; JAUNDICE; KIDNEY DISEASE; LIPID STORAGE; LIPODYSTROPHY; LIPOMATOSIS; MEDICAL DECISION MAKING; MYOPATHY; NAUSEA; NEPHROLITHIASIS; OBESITY; PATIENT ATTITUDE; PATIENT COMPLIANCE; PRIORITY JOURNAL; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL; SELF CONCEPT; TRANSIENT ISCHEMIC ATTACK; TREATMENT OUTCOME; TREATMENT PLANNING; TREATMENT WITHDRAWAL; UNSTABLE ANGINA PECTORIS; VOMITING;

EID: 1842538141     PISSN: 15254135     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Conference Paper

References (66)

1. Lenert LA, Feddersen M, Sturley A, et al. Adverse effects of medications and trade-offs between length of life and quality of life in human immunodeficiency virus infection. Am J Med. 2002;113(3):229-232.
2. Jordan R, Gold L, Cummins C, Hyde C. Systematic review and meta-analysis of evidence for increasing numbers of drugs in antiretroviral combination therapy. BMJ 2002;324:1-10.
3. Katzenstein TL, Kirk O, Pedersen C, et al. The Danish protease inhibitor study: a randomized study comparing the virological efficacy of 3 protease inhibitor-including regimens for the treatment of human immunodeficiency virus type 1 infection. J Infect Dis. 2000;182 (3):744-750.
4. Duran S, Spire B, Raffi F, et al. Self-reported symptoms after initiation of a protease inhibitor in HIV-infected patients and their impact on adherence to HAART. HIV Clin Trials. 2001;2(1):38-45.
5. Sherman DS, Fish DN. Management of protease inhibitor-associated diarrhea. Clin Infect Dis. 2000;30(6):908-914.
6. Watson A, Samore MH, Wanke CA. Diarrhea and quality of life in ambulatory HIV-infected patients. Dig Dis Sci. 1996;41(9):1794-1800.
7. Lenderking WR, Gelber RD, Cotton DJ, et al. Evaluation of the quality of life associated with zidovudine treatment in asymptomatic human immunodeficiency virus infection. The AIDS Clinical Trials Group. N Engl J Med. 1994;330(11):738-743.
8. Kosmyna JM, MacArthur RD. The incidence and severity of diarrhea in HIV+ patients from a large, urban medical center who have taken nelfinavir in the past twelve months [abstract 12392]. In: Conference Record of the Twelfth World AIDS Conference. Geneva: Marathon Multimedia, 1998.
9. Grunfeld C. Basic science and metabolic disturbances [abstract TuOr158]. In: Abstracts of the 14th International AIDS Conference; Barcelona, Spain, July 7-12, 2002.
10. Gripshover B, Tien PC, Saag M, et al. Lipoatrophy is the dominant feature of the lipodystrophy syndrome in HIV-infected men [abstract 732]. In: Abstracts of the 10th Conference on Retroviruses and Opportunistic Infections; Boston; February 10-14, 2003.
11. Saag M, Tien PC, Gripshover B, et al. Body composition in HIV+ men with and without peripheral lipoatrophy is different than controls [abstract 733]. In: Abstracts of the 10th Conference on Retroviruses and Opportunistic Infections; Boston, February 10-14, 2003.
12. Zolopa A, Benson C, Bacchetti P, et al. Buffalo hump in men with HIV infection: larger, but not more common [abstract 734]. In: Abstracts of the 10th Conference on Retroviruses and Opportunistic Infections; Boston, February 10-14, 2003.
13. Martinez E, Mocroft A, Garcia-Viejo MA, et al. Risk of lipodystrophy in HIV-1-infected patients treated with protease inhibitors: a prospective cohort study. Lancet. 2001;357(9256):592-598.
14. Scarsella J, Dieterich DT, Graham NMH, et al. Predictors of lipodystrophy in HIV-infected patients from the CHORUS observational cohort [abstract 1286]. In: Abstracts of the 40th Annual Meeting of the Interscience Conference on Antimicrobial Agents and Chemotherapy. Toronto, September 17-20, 2000.
15. Dubé M, Zackin R, Tebas P, et al. Prospective study of regional body composition in antiretroviral-naive subjects randomized to receive zidovudine + lamivudine or didanosine + stavudine combined with nelfinavir, efavirenz or both: A5005s, a substudy of ACTG 384 [abstract 27]. In: Abstracts of the 4th International Workshop on Adverse Drug Reactions and Lipodystrophy in HIV. San Diego, September 22-25, 2002.
16. Cohen C, Shen Y, Rode R, et al. Effect of nucleoside (NRTI) intensification on prevalence of morphologic abnormalities (MoAs) at year 5 of ritonavir (RTV) plus saquinavir (SQV) therapy in an HIV-infected cohort [abstract 683]. In: Abstracts of the 9th Conference on Retroviruses and Opportunistic Infections; Seattle, February 24-28, 2002.
17. Mallon PW, Miller J, Cooper DA, Carr A. Prospective evaluation of the effects of antiretroviral therapy on body composition in HIV-1-infected men starting therapy. AIDS. 2003;17(7):971-979.
18. Riddler SA, Smit E, Cole SR, et al. Impact of HIV infection and HAART on serum lipids in men. JAMA. 2000;289:2978-82.
19. Mallal SA. Managing regimen difficulties: meeting the challenges of safety and tolerability. Adv Studies Med 2003;3(Nov):S15-S20. Also available at http://www.jhasim.com/template.cfm?TEMPLATE=include_programinfo.cfm&ID= 57&ZoneID=8&TYPE=text.
20. Purnell JQ, Zambon A, Knopp RH, et al. Effect of ritonavir on lipids and post-heparin lipase activities in normal subjects. AIDS. 2000;14(1):51-57.
21. Periard D, Telenti A, Sudre P, et al. Atherogenic dyslipidemia in HIV-infected individuals treated with protease inhibitors. The Swiss HIV Cohort Study. Circulation. 1999;100(7):700-705.
22. Kumar P, Rodriguez-French A, Thompson M, et al. Prospective Study of Hyperlipidemia in ART-naïve subjects taking Trizivir (TZV), Combivir (COM)/nelfinavir (NFV), or stavudine (d4T)/lamivudine (3TC)/NFV) [abstract 709]. In: Abstracts of the 2nd IAS Conference on HIV Pathogenesis and Treatment; Paris, July 13-16, 2003.
23. Kumar P, Rodriguez-French A, Thompson M, et al. Prospective Study of Hyperlipidemia in ART-naïve subjects taking Combivir/abacavir (COM/ABC), COM/nelfinavir (NFV), or stavudine (d4T)/lamivudine (3TC)/NFV (ESS40002) [abstract 33]. In: Abstracts of the 9th Conference on Retroviruses and Opportunistic Infections; Seattle, February 24-28, 2002.
24. Simon GL, Liappis AP, Granger SL, et al. Antiretroviral therapy-induced changes in lipoprotein subclass phenotype: comparison of protease inhibitor and non-nucleoside reverse transcriptase inhibitor regimens. Antiviral Therapy. 2002;7:L9.
25. Dragsted UB, Gerstoft J, Pedersen C, et al. Randomized trial to evaluate indinavir/ritonavir versus saquinavir/ritonavir in human immunodeficiency virus type 1-infected patients: the MaxCmin1 Trial. J Infect Dis. 2003;188:635-642.
26. Gerstoft J, Dragsted UB, Cahn P, et al. Final analysis of a randomised trial to evaluate safety and efficacy of indinavir/ritonavir versus saquinavir/ritonavir in adult HIV-1 infection: the MaxCmin1 trial [abstract H-172]. In: Abstracts of the 42nd Interscience Conference on Antimicrobial Agents and Chemotherapy; San Diego, September 27-30, 2002.
27. Youle M, Gerstoft J, Fox Z, et al. The final 48 week analysis of a phase IV, randomised, open-label, multicentre trial to evaluate safety and efficacy of lopinavir/ritonavir (400/100 mg bid) vs saquinavir/ritonavir (1000/100 mg bid) in adult HIV-1 infection: the MaxCMin2 study [abstract LB23]. In: Program and abstracts of the 2nd International AIDS Society Conference on HIV Pathogenesis and Treatment; Paris, July 13-16, 2003.
28. González de Requena D, Gallego O, Blanco F, et al. Lopinavir drug levels predict the virological and immunological outcome as well as lipid elevations [abstract 525]. In: Abstracts of the 10th Conference on Retroviruses and Opportunistic Infections; Boston, February 10-14, 2003.
29. Murphy RL, Brun S, Hicks C, et al. ABT-378/ritonavir plus stavudine and lamivudine for the treatment of antiretroviral-naive adults with HIV-1 infection: 48-week results. AIDS. 2001;15:F1-F9.
30. Currier J. Lipids and insulin resistance in men. Losses and gains: insights from the preliminary results of the fat redistribution and metabolic change in HIV Infection Study (FRAM). Unabstracted oral presentation at the Institutional Symposium at the 2nd International AIDS Society Conference on HIV Pathogenesis and Treatment. Paris, July 13-16, 2003.
31. Van der Horst C. Lipids and insulin resistance in women. Losses and gains: insights from the preliminary results of the fat redistribution and metabolic change in HIV Infection Study (FRAM). Unabstracted oral presentation at the Institutional Symposium at the 2nd International AIDS Society Conference on HIV Pathogenesis and Treatment. Paris, July 13-16, 2003.
32. Holmberg S, Moorman A, Tong T, et al. Protease inhibitor use and adverse cardiovascular outcomes in ambulatory HIV patients [abstract 698-T]. In: Abstracts of the 9th Conference on Retroviruses and Opportunistic Infections; Seattle, February 24-28, 2002.
33. Rickerts V, Brodt H, Staszewski S, et al. Incidence of myocardial infarctions in HIV-infected patients between 1983 and 1998: the Frankfurt HIV-cohort study. Eur J Med Res. 2000;5(8):329-333.
34. Mary-Krause M, Cotte L, Partisani M, et al. Impact of Treatment with Protease Inhibitor (PI) on Myocardial Infarction (MI) Occurrence in HIV-Infected Men [abstract 657]. In: Abstracts of the 8th Conference on Retroviruses and Opportunistic Infections; Chicago, February 4-8, 2001.
35. Mary-Krause M., Cotte L, Simon A, et al. Increased risk of myocardial infarction with duration of protease inhibitor therapy in HIV-infected men. AIDS. 2003;17:2479-2486.
36. Friis-Møller N, Weber R, Reiss P, et al. Cardiovascular disease risk factors in HIV patients-association with antiretroviral therapy. Results from the DAD study. AIDS. 2003;17(8):1179-1193.
37. Friis-Moller N, Sabin CA, Weber R, et al. Combination antiretroviral therapy and the risk of myocardial infarction. N Engl J Med. 2003;349:1993-2003.
38. Moore RD, Keruly JC, Lucas G. Increasing incidence of cardiovascular disease in HIV-infected persons in care [abstract 132]. In: Abstracts of the 10th Conference on Retroviruses and Opportunistic Infections; Boston, February 10-14, 2003.
39. Klein D, Hurley LB, Quesenberry CP Jr, et al. Do protease inhibitors increase the risk for coronary heart disease in patients with HIV-1 infection? J Acquir Immune Defic Syndr. 2002;30(5):471-477.
40. Klein D, Hurley L. Hospitalizations for coronary heart disease and myocardial infarction among men with HIV-1 infection: additional follow-up [abstract 747]. In: Abstracts of the 10th Conference on Retroviruses and Opportunistic Infections; Boston, February 10-14, 2003.
41. Bozzette SA, Ake CF, Tam HK, et al. Cardiovascular and cerebrovascular events in patients treated for human immunodeficiency virus infection. N Engl J Med. 2003;348(8):702-710.
42. Dubé MP, Stein JH, Aberg JA, et al. Guidelines for the evaluation and management of dyslipidemia in human immunodeficiency virus (HIV)-infected adults receiving antiretroviral therapy: recommendations of the HIV Medical Association of the Infectious Disease Society of America and the Adult AIDS Clinical Trials Group. Clin Infect Dis. 2003;37:613-27.
43. Mulligan K, Tai VW, Schambelan M. Cross-sectional and longitudinal evaluation of body composition in men with HIV infection. J Acquir Immune Defic Syndr Hum Retrovirol. 1997;15(1):43-48.
44. Martinez E, Conget I, Lozano L, et al. Reversion of metabolic abnormalities after switching from HIV-1 protease inhibitors to nevirapine. AIDS. 1999;13(7):805-810.
45. Justman JE, Benning L, Danoff A, et al. Protease inhibitor use and the incidence of diabetes mellitus in a large cohort of HIV-infected women. J Acquir Immune Defic Syndr. 2003;32(3):298-302.
46. Walli R, Herfort O, Michl GM, et al. Treatment with protease inhibitors associated with peripheral insulin resistance and impaired oral glucose tolerance in HIV-1-infected patients. AIDS. 1998;12(15):F167-173.
47. Beatty G, Khalili M, Abbasi F, et al. Quantification of insulin-mediated glucose disposal in HIV-infected individuals: comparison of patients treated and untreated with protease inhibitors. J Acquir Immune Defic Syndr. 2003;33(1):34-40.
48. Noor MA, Lo JC, Mulligan K, et al. Metabolic effects of indinavir in healthy HIV-seronegative men. AIDS. 2001;15:F11-18.
49. Noor MA, Seneviratne T, Aweeka FT, et al. Indinavir acutely inhibits insulin-stimulated glucose disposal in humans: a randomized, placebo-controlled study. AIDS. 2002;16:F1-8.
50. Murata H, Hruz PW, Mueckler M. Indinavir inhibits the glucose transporter isoform Glut4 at physiologic concentrations. AIDS. 2002;16:859-863.
51. Dubé MP, Qian D, Edmondson-Melancon H, et al. Prospective, intensive study of metabolic changes associated with 48 weeks of amprenavir-based antiretroviral therapy. Clin Infect Dis. 2002b;35(4):475-481.
52. Squires KE, Thiry A, Giordano M, et al. Atazanavir (ATV) QD and efavirenz (EFV) QD with fixed-dose ZDV+3TC: comparison of antiviral efficacy and safety through Wk 24 (AI424-034) [abstract H-1076]. In: Abstracts of the 42nd Interscience Conference on Antimicrobial Agents and Chemotherapy; San Diego, September 27-30, 2002.
53. Nieto-Cisneros I, Zala C, Fessel WJ, et al. Antiviral efficacy, metabolic changes and safety of atazanavir versus lopinavir/ritonavir in combination with two NRTIs in patients who have experienced virological failure with prior PI-including regimen(s): 24-week results from BMS AI424-043 [abstract 117]. In: Program and abstracts from the 2nd IAS Conference on HIV Pathogenesis and Treatment; Paris, July 13-16, 2003.
54. Badero R, DeJesus E, Lazzarin A, et al. Efficacy and safety of atazanavir (ATV) with ritonavir (RTV) or saquinavir (SQV) versus lopinavir/ritonavir (LPV/rtv) in combination with tenofovir (TFV) and one NRTI in patients who have experienced virologic failure to multiple HAART regimens [abstract 118]. In: Abstracts of the 2nd International Conference on HIV Pathogenesis and Treatment. Paris, July 11-14, 2003.
55. Reyataz prescribing information. Bristol-Myers Squibb Company. Princeton, NJ.
56. Food and Drug Administration Antiviral Drugs Advisory Committee. Briefing Document BMS-232632. May 13, 2003.
57. Rodriguez-French A, Boghossian J, Gray GE, et al. The NEAT study: a 48-week open-label study to compare the antiviral efficacy and safety of GW433908 versus nelfinavir in antiretroviral therapy-naive HIV-1-infected patients. J Acquir Immune Defic Syndr. 2004;35:22-32.
58. Schurmann D, Gathe J, Sanne I, et al. Efficacy and safety of GW 433908/r once daily in therapy-naïve subjects, 48 week results, the SOLO Study [abstract PL-14.4]. In: Abstracts of the 6th International Congress on Drug Therapy in HIV Infection; Glasgow, UK, November 17-21, 2002.
59. Executive Summary of The Third Report of The National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, And Treatment of High Blood Cholesterol In Adults (Adult Treatment Panel III). JAMA. 2001;285:2486-2497.
60. DeJesus E, et al. The context study: efficacy and safety of GW433908/RTV in PI-experienced subjects with virological failure (24-week results) [abstract 178]. In: Abstracts of the 10th Conference on Retroviruses and Opportunistic Infections; Boston, February 10-14, 2003.
61. Chong KT, Pagano PJ. In vitro combination of PNU-140690, a human immunodeficiency virus type 1 protease inhibitor, with ritonavir against ritonavir-sensitive and -resistant clinical isolates. Antimicrob Agents Chemother. 1997;41(11):2367-2373.
62. Curry R, Markowitz M, Slater L, et al. Safety and efficacy of tipranavir, a non-peptidic protease inhibitor, in multiple PI-failure patients (BI 1182.2) [abstract 3]. In: Program and abstracts of The 1st IAS Conference on HIV Pathogenesis and Treatment; Buenos Aires, July 8-11, 2001.
63. Gathe J, Kohlbrenner VM, Pierone G, et al. Tipranavir/Ritonavir Demonstrates Potent Efficacy in Multiple Protease Inhibitor Experienced Patients: BI 1182.52 [abstract 179]. In: Abstracts of the 10th Conference on Retroviruses and Opportunistic Infections; Boston, February 10-14, 2003.
64. Arasteh K, Clumeck N, Pozniak A, et al. First clinical results on antiretroviral activity, pharmacokinetics and safety of TMC114, an HIV-1 protease inhibitor in multiple PI-experienced patients [abstract 8]. In: Abstracts of the 10th Conference on Retroviruses and Opportunistic Infections; Boston, February 10-14, 2003.
65. Taburet AM, Piketty C, Gérard L, et al. Pharmacokinetic parameters of atazanavir/ritonavir when combined to tenofovir in HIV infected patients with multiple treatment failures: a sub-study of Puzzle2-ANRS 107 Trial [abstract 537]. In: Abstracts of the 10th Conference on Retroviruses and Opportunistic Infections; Boston, February 10-14, 2003.
66. Lexiva prescribing information. GlaxoSmithKline, Research Triangle Park, NC. October 2003.